Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.
Our lead clinical-stage candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-positive solid tumors. Data from our completed Phase 1 dose-escalation trial support the advancement of BDC-1001 into Phase 2 studies.
Bolt is also advancing BDC-3042, a proprietary myeloid modulating agonistic antibody targeting Dectin-2. BDC-3042 is designed to reprogram tumor-associated macrophages (TAMs) into immunostimulatory cells that enhance innate and adaptive anti-tumor immunity. Preclinical data support the advancement of BDC-3042 into the clinic in 2023.
September 12, 2023
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042Read More
September 5, 2023
Bolt Biotherapeutics to Participate in September Investor ConferencesRead More
August 7, 2023
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateRead More
September 12, 2023 at 3:35 PM EDT
Morgan Stanley 21st Annual Global Healthcare Conference Read More
June 3, 2023 at 9:00 AM EDT
2023 American Society of Clinical Oncology (ASCO) Annual Meeting Read More
April 17, 2023 at 1:30 PM EDT
American Association of Cancer Research (AACR) Annual Meeting 2023 Read More